The University of Puerto Rico (UPR) ACTU Unit has accrued significant numbers of patients for several important clinical trials and has developed an infrastructure group. In the last 36 months, the UPR Adult ACTU has participated in 18 different ACTG trials. A total of 231 new patients have been accrued to participate in studies and sub-studies. All of the patients are Hispanics and are stratified as follows: 36 percent females, 65 percent males, 21.6 percent Injection Drug Users (IDU). The UPR Adult ACTU plans for immediate research in collaboration with the Pharmacy Research Section to perform Phase I and II pharmacokinetic (PK) and intracellular concentration trials, as well as clinical trials in naive and heavily pre-treated individuals, women and IDUs. They will embark in such important aspects of metabolic complications and novel approaches with immunological enhancers, among others. The UPR ACTU, as a part of the ACTG, offers an opportunity to study variation patterns in the epidemiological and clinical manifestations of AIDS in minority groups. It also provides for much needed supportive and therapeutic alternatives to patients.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI034832-10
Application #
6488951
Study Section
Special Emphasis Panel (ZAI1-PSS-A (S1))
Program Officer
Matula, Margaret A
Project Start
1996-01-01
Project End
2004-12-31
Budget Start
2002-01-01
Budget End
2002-12-31
Support Year
10
Fiscal Year
2002
Total Cost
$1,485,785
Indirect Cost
Name
University of Puerto Rico Med Sciences
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
San Juan
State
PR
Country
United States
Zip Code
00936
Winham, Stacey J; Slater, Andrew J; Motsinger-Reif, Alison A (2010) A comparison of internal validation techniques for multifactor dimensionality reduction. BMC Bioinformatics 11:394
Skowron, Gail; Spritzler, John G; Weidler, Jodi et al. (2009) Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects. J Acquir Immune Defic Syndr 50:250-8
Sattler, Fred R; Rajicic, Natasa; Mulligan, Kathleen et al. (2008) Evaluation of high-protein supplementation in weight-stable HIV-positive subjects with a history of weight loss: a randomized, double-blind, multicenter trial. Am J Clin Nutr 88:1313-21
Twigg Iii, Homer L; Weiden, Michael; Valentine, Fred et al. (2008) Effect of highly active antiretroviral therapy on viral burden in the lungs of HIV-infected subjects. J Infect Dis 197:109-16
Gulick, Roy M; Lalama, Christina M; Ribaudo, Heather J et al. (2007) Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression. AIDS 21:813-23
Shikuma, Cecilia M; Yang, Yang; Glesby, Marshall J et al. (2007) Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095). J Acquir Immune Defic Syndr 44:540-50
Bosch, Ronald J; Bennett, Kara; Collier, Ann C et al. (2007) Pretreatment factors associated with 3-year (144-week) virologic and immunologic responses to potent antiretroviral therapy. J Acquir Immune Defic Syndr 44:268-77
Gulick, Roy M; Ribaudo, Heather J; Shikuma, Cecilia M et al. (2006) Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA 296:769-81
Swindells, Susan; DiRienzo, A Gregory; Wilkin, Timothy et al. (2006) Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA 296:806-14
Gripshover, Barbara M; Ribaudo, Heather; Santana, Jorge et al. (2006) Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118). Antivir Ther 11:619-23

Showing the most recent 10 out of 23 publications